![Anemia akibat perdarahan pdf](https://kumkoniak.com/59.jpg)
2012 38:433-46.įavaloro EJ, Bonar R, Duncan E, Earl G, Low J, Aboud M, et al. Acquired Inhibitors of Coagulation Factors: Part I-Acquired Hemophilia A. 2012 44(4):293-302.Ĭoppola A, Favaloro EJ, Tufano A, Minno MNDD, Cerbone AM, Franchini M. Laboratory identification of factor inhibitors: an update. Acquired hemophilia A: emerging treatment options. Janbain M, Leissinger CA, Kruse-Jarres R. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. 2006:432-7.īaudo F, Collins P, Huth-Kuhne A, Le´vesque H, Marco P, Nemes L, et al. Acquired Factor VIII Inhibitors: Pathophysiology and Treatment. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. 1989 74(5):1618-26.įulcher CA, Mahoney SdG, Roberts JR, Kasper CK, Zimmerman TS. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Scandella D, Mattingly M, Graaf Sd, Fulcher CA. Anti-factor VIII antibodies: a 2005 update.
![anemia akibat perdarahan pdf anemia akibat perdarahan pdf](https://image.slidesharecdn.com/anemiaferroprivaeperniciosa-120904082359-phpapp02/95/anemia-ferropriva-e-perniciosa-22-728.jpg)
![anemia akibat perdarahan pdf anemia akibat perdarahan pdf](https://3.bp.blogspot.com/-eQsxGjPYZfk/WvhgKGHAFeI/AAAAAAAAShQ/TOybNjTuxrw6VEHMYjwqCdIjVzAtXRsEQCEwYBhgL/s1600/anemia%2B1%2B-%2Bcover.jpg)
Lavigne-Lissalde G, Schved J-F, Granier C, Villard S. HLA genotype in patients with acquired haemophilia A. Pavlova A, Zeitler H, Scharrer I, Brackmann HH, Oldenburg J. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. 2008 14:355-60.Įhrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, et al. Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls. Pavlova A, Diaz-Lacava A, Zeitler H, Satoguina J, Niemann B, Krause M, et al. Assessment of acquired hemophilia patient demographics in the United States: the Hemostasis and Thrombosis Research Society Registry. Kessler CM, Ma AD, Al-Mondhiry HAB, Gut RZ, Cooper aDL. Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study. Holstein K, Liu X, Smith A, Knobl P, Klamroth R, Geisen U, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Knoebl P, Marco P, Baudo F, Collins P, Huth-Kuhne A, Nemes L, et al. Acquired hemophiliaAin the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’Organisation. 2012 38:447-53.Ĭollins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. Acquired Inhibitors of Coagulation Factors: Part II. Autoantibodies to coagulation factors: From pathophysiology to diagnosis and therapy. 2015 40(3).Ĭugno M, Gualtierotti R, Tedeschi A, Meroni PL. Clinical and Laboratory Approaches to Hemophilia A. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A.
![anemia akibat perdarahan pdf anemia akibat perdarahan pdf](https://3.bp.blogspot.com/-5HxOnwucLkY/XHt7M9HvwZI/AAAAAAAABzk/oskgoU_h7Wk35gvDQh4aTm3sSVvOxKKygCLcBGAs/s1600/thalassemia.jpg)
Moreover, therapeutical choice and side effects control require special consideration to achieve hemostasis and durable remission.Ĭollins P, Baudo F, Huth-Kühne A, Ingerslev J, Kessler CM, Castellano MEM, et al. Treatment for acquired hemophilia A encompasses hemostatic therapy, immunosuppression, and treatment of underlying disease. However, several challenges lay within patients’ management strategy, such as diagnosis workup and therapeutical choices. Prolonged activated partial thromboplastin time, uncorrected mixing test, low FVIII activity, and detection of FVIII inhibitors support the diagnosis of acquired Hemophilia A.
![anemia akibat perdarahan pdf anemia akibat perdarahan pdf](http://2.bp.blogspot.com/-YE_n1hf-4tI/TrKQdxDeSHI/AAAAAAAAAB4/JMyyg6QYMGQ/s320/images.jpeg)
Hemophilia A occurs due to the development of an antibody against FVIII, moreover up to half of these cases have underlying conditions. Pemilihan terapi serta pengendalian terhadap efek samping dari pengobatan memerlukan perhatian khusus agar tercapai hemostasis dan remisi yang bertahan lama.Īcquired Hemophilia A can potentially cause life-threatening conditions due to profuse bleeding, but this autoimmune disease is mostly underdiagnosed. Rintangan dalam manajemen pasien dimulai dari penegakan diagnosis hingga penentuan terapi, baik terapi hemostatik, imunosupresi, serta pengobatan penyakit penyerta. Pemanjangan activated partial thromboplastin time, mixing test yang tidak terkoreksi, rendahnya aktivitas FVIII, dan bukti inhibitor FVIII mendukung penegakan diagnosis Hemofilia A yang didapat. Penyakit autoimun akibat pembentukan autoantibodi (inhibitor) terhadap FVIII ini hampir setengahnya memiliki gangguan lain yang mendasari. Hemofilia A yang didapat adalah penyakit yang jarang terdiagnosis dan seringkali salah terdiagnosis namun berpotensi menyebabkan perdarahan yang mengancam nyawa.
![Anemia akibat perdarahan pdf](https://kumkoniak.com/59.jpg)